Overview
Publication
J Acquir Immune Defic Syndr. 2016 Dec 1; 73(4):365-373.
PubMed ID: 27792681
Title
Distinct HIV-1 neutralization potency profiles of Ibalizumab-based bispecific antibodies
Authors
Song R, Pace C, Seaman MS, Fang Q, Sun M, Andrews CD, Wu A, Padte NN, Ho DD
Abstract
Preexposure prophylaxis using antiretroviral agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which is thought to be largely due to the varying degrees of adherence to a daily intervention in the populations. Passive immunization using broadly neutralizing antibodies (bNAbs) against HIV-1, with their relatively long half-life and favorable safety profile, could provide an alternative to daily preexposure prophylaxis. However, most bNAbs have a limited breadth, only neutralizing 70%-90% of all HIV-1 strains.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.
Related Studies
No related studies